Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Epileptic seizure
Acute adrenal crisis
Anaphylactic shock
Severe asthma crisis
Migraines and cluster headaches
Opioid overdose
Rheumatoid arthritis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
Financial releases
Financial releases
Release date
Min
Max
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Apply
2024/06/26
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
Read the release
2024/06/12
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
Read the release
2024/06/04
Crossject announces highly successful closing of its €8 million rights offering
Read the release
2024/05/30
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
Read the release
2024/05/02
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
Read the release
2024/04/30
Crossject announces a rights issue for approximately €8 million to support the registration of ZEPIZURE® and its continued expansion in the U.S.
Read the release
2024/04/25
Crossject reports audited financial results for 2023
Read the release
2024/04/02
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
Read the release
2024/03/08
Crossject gender equality score reaches 96/100 in 2024
Read the release
2024/02/27
Crossject obtains a financing up to €12 million, in two tranches
Read the release
Pagination
Current page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
Next page
Next ›
Last page
Last »
